The collaboration will use Caprion’s CellCarta® proteomics platform to support biomarker discovery. Caprion will identify pharmacodynamic biomarkers in plasma resulting from the administration of Berlex compounds in pre-clinical development.
"Caprion is looking forward to working with Berlex on their pre-clinical therapeutic candidates," noted Dr. Daniel Chelsky, Chief Scientific Officer at Caprion.
"We believe Caprion’s capabilities in the discovery of protein biomarkers will significantly impact our partner’s development efforts."
Caprion’s proprietary proteomics platform profiles the expression and identity of proteins detected in tissues and blood plasma.